Health Source: JKN2301 dry suspension has been approved for clinical trials.

Health Element Announcement: The company has received the "Notice of Approval for Clinical Trial of Drugs" issued by the National Medical Products Administration, approving the clinical trial of JKN2301 dry suspension. This drug is suitable for children aged 2 to 12 with uncomplicated influenza A and B, and is an innovative drug developed with the patented compound mapracilsavir. The dosage can be flexibly adjusted according to the child's weight, improving medication compliance in children.